A settlement has been reached to resolve False Claims Act allegations against Qualitest Pharmaceuticals Inc.
The allegations arose from a lawsuit that claimed Qualitest Pharmaceuticals, a generic drug maker, owned by Endo International Plc, illegally labeled multivitamins that contained fluoride.
New York Attorney General disclosed that Qualitest's false labeling caused healthcare professionals to submit false reimbursement claims to Medicaid and federal health care plans and that it also put patients in higher risk of cavities.
The multivitamins contained only half of the fluoride amount recommended by the United States Food and Drug Administration.
Under terms of the settlement, Alabama-based Qualitest will pay 47 participating states and the federal government a total of $39 million to resolve the unlawful mislabeling allegations.
